OncoPharm

Latest Episodes:

Updates In RCC, Pancreatic Cancer, And Skin Cancer In SOT Mar 28, 2024

Show notes

Discussing four papers that caught our eyes from the last few weeks: Pazopanib vs. placebo following metastatectomy. Always concerning when placebo has an OS advantage. ECOG-ACRIN E2810: https://doi.org/10.1200/JCO.23.01544 Gemcitabine vs. Gem + Paclitaxel (Taxol) in pancreatic cancer patients after FOLFIRINOX: https://doi.org/10.1200/JCO.23.00795 An RNA assay to predict gemcitabine sensitivity: https://doi.org/10.1200/JCO.22.02668 Management of skin cancers with ICIs in kidney transplant patients: https://doi.org/10.1200/JCO.23.02570

Colon Cancer Screening Wars Mar 14, 2024

Show notes

Two recent publications suggest more people may be choosing non-colonoscopy screening practices in the future. One is a new stool DNA test, while the other is a blood test. How do they compare to the gold standard of colonoscopy? Cell-free DNA blood test: DOI: 10.1056/NEJMoa2304714 Next generation stool DNA test: DOI: 10.1056/NEJMoa2310336

Bladder Cancer Updates Mar 07, 2024

Show notes

EV-302 is finally published, and you have to squint to find any major critiques. Enfortumab bedouin + pembrolizumab fully arrives as a standard 1st-line regimen of advanced urothelial cancer. Also, nivolumab gets a 1st-line FDA approval for urothelial carcinoma in conjunction with cisplatin + gemcitabine based on CHECKMATE-901.

SPARED & D-TORCH Feb 29, 2024

Show notes

Two nice studies have been recently published in the supportive care realm. SPARED asks if we can omit dexamethasone on days 2-4 following cisplatin-based chemotherapy. D-TORCH asks if topical diclofenac can prevent capecitabine-induced hand-foot syndrome. SPARED: https://doi.org/10.1038/s41416-023-02493-7 D-TORCH: https://doi.org/10.1200/JCO.23.01730

Lifileucel & FLAURA2 Updates Feb 22, 2024

Show notes

An exciting new cellular therapy, lifileucel, is approved for metastatic melanoma. The FLAURA2 trial of osimertinib + chemotherapy has led to an FDA approval, but questions remain about a possible new standard of care. And a few minor updates on tepotinib.

NAPOLI 3, POUT, & Ivosidenib - Azole DDIs Feb 15, 2024

Show notes

New updates on metastatic pancreatic cancer (NAPOLI-3), upper tract urothelial cancer (POUT), and the drug-drug interaction between ivosidenib and azole antifungals. NAPOLI 3: https://doi.org/10.1016/S0140-6736(23)01366-1 POUT (final OS): https://doi.org/10.1200/JCO.23.01659 Ivosidenib Azole Antifungal DDIs: https://doi.org/10.1002/cncr.35251

Small Cell Carcinoma, Prostate Edition Feb 08, 2024

Show notes

You know about small cell lung cancer, but let's talk about small cell carcinoma of the prostate.

Rethinking Some Fundamental Considerations Feb 01, 2024

Show notes

In oncology we are always asking questions about which treatment option is best. And that focus on the next best treatment may prevent us from rethinking some fundamentals of current practice. Three recent studies illustrate this and made me ask: Do we need a Port or PICC for every testicular cancer patient? Study: https://doi.org/10.1200/OP.23.00580 Editorial: https://doi.org/10.1200/OP.23.00730 Is vaginal estrogen safe if breast cancer patients? Study: https://jamanetwork.com/journals/jamaoncology/article-abstract/2811413 Does paclitaxel work differently than we always thought? Study: https://doi.org/10.1371/journal.pbio.3002339

Jan 2024 Updates... Jan 25, 2024

Show notes

...on FDA approvals for belzutifan for RCC, pembrolizumab + cisplatin/RT for cervical cancer, erdafitinib (FGFR3 alterations only) for bladder cancer. Plus, early morning ICIs (https://doi.org/10.1016/j.ejca.2024.113571) & FLAG-Ida-GO in AML from NCRI AML 19 (https://doi.org/10.1200/JCO.23.00943)

Development Of Generic Lenalidomide with Dr. Ryan Beechinor Jan 10, 2024

Show notes

Special guest Ryan Beechinor joins the pod to discuss his recent paper on the obstacles in the development of generic lenalidomide. It's a fantastic read, and this episode will be a fantastic listen! Link: https://doi.org/10.1016/j.jcpo.2023.100446

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected